Results 201 to 210 of about 312,758 (261)
Anti-HIV-1 Effect of the Fluoroquinolone Enoxacin and Modulation of Pro-Viral hsa-miR-132 Processing in CEM-SS Cells. [PDF]
Noncoding RNASchlösser V +11 more
europepmc +1 more source
Development of Anti-HIV Therapeutics: From Conventional Drug Discovery to Cutting-Edge Technology. [PDF]
Pharmaceuticals (Basel)Sun Y, Wang L.
europepmc +1 more source
CXCR4 Is a Potential Target for Anti-HIV Gene Therapy. [PDF]
Int J Mol SciProkopovich AK +3 more
europepmc +1 more source
Anti-HIV activity in traditional Chinese medicine: clinical implications of monomeric herbal remedies and compound decoctions. [PDF]
Front Med (Lausanne)Zhang N +6 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Molecular Biotechnology, 1997
HIV is an RNA virus that replicates intracellularly through various RNA intermediates. Several of these can be targeted by ribozymes (catalytic RNA molecules), and a number of investigators, including this group, have demonstrated the ability of ribozymes to suppress HIV replication in this way.
L Q, Sun +3 more
openaire +5 more sources
HIV is an RNA virus that replicates intracellularly through various RNA intermediates. Several of these can be targeted by ribozymes (catalytic RNA molecules), and a number of investigators, including this group, have demonstrated the ability of ribozymes to suppress HIV replication in this way.
L Q, Sun +3 more
openaire +5 more sources
Current Protein & Peptide Science, 2004
The cyclotides are a recently discovered, structurally unique family of bioactive plant peptides. Their discovery spawned a series of structural analyses, synthetic efforts, and studies to define the biosynthesis and biological properties of these novel peptide metabolites.
Kirk R, Gustafson +2 more
openaire +2 more sources
The cyclotides are a recently discovered, structurally unique family of bioactive plant peptides. Their discovery spawned a series of structural analyses, synthetic efforts, and studies to define the biosynthesis and biological properties of these novel peptide metabolites.
Kirk R, Gustafson +2 more
openaire +2 more sources
Pharmacogenetics of Anti-HIV Drugs
Annual Review of Pharmacology and Toxicology, 2008Pharmacogenetics holds promise in HIV treatment because of the complexity and potential toxicity of multidrug therapies that are prescribed for long periods. Thus far, few candidate genes have been examined for a limited number of allelic variants, but a number of confirmed associations have already emerged.
Telenti A, Zanger UM
openaire +3 more sources
Expert Opinion on Emerging Drugs, 2005
There are now exactly 20 anti-HIV drugs licenced (approved) for clinical use, and > 30 anti-HIV compounds under (pre)clinical development. The licensed anti-HIV drugs fall into five categories: nucleoside reverse transcriptase inhibitors (NRTIs: zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir and emtricitabine); nucleotide reverse ...
openaire +2 more sources
There are now exactly 20 anti-HIV drugs licenced (approved) for clinical use, and > 30 anti-HIV compounds under (pre)clinical development. The licensed anti-HIV drugs fall into five categories: nucleoside reverse transcriptase inhibitors (NRTIs: zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir and emtricitabine); nucleotide reverse ...
openaire +2 more sources
Vaccine, 1988
There is a great deal of experience on the development and testing of antiviral vaccines but, in the case of HIV, it will be necessary to analyse carefully our understanding of the biology of the organism, the natural history and pathology of the disease (in particular immunity or resistance to infection or clinical symptoms), the possible sources of ...
openaire +2 more sources
There is a great deal of experience on the development and testing of antiviral vaccines but, in the case of HIV, it will be necessary to analyse carefully our understanding of the biology of the organism, the natural history and pathology of the disease (in particular immunity or resistance to infection or clinical symptoms), the possible sources of ...
openaire +2 more sources
2008
Modern combination drug therapy has substantially improved the clinical management of HIV-1 infection. Still, the emergence of drug-resistant variants eventually leads to therapy failure in most patients. The selection of an optimal follow-up regimen is complicated by an ever-increasing range of possible drug combinations.
openaire +3 more sources
Modern combination drug therapy has substantially improved the clinical management of HIV-1 infection. Still, the emergence of drug-resistant variants eventually leads to therapy failure in most patients. The selection of an optimal follow-up regimen is complicated by an ever-increasing range of possible drug combinations.
openaire +3 more sources